【品大事】 激智科技：受让1575万元投资基金份额并投资于AI大模型公司 激智科技公告，与弘信创业工场投资集团股份有限公司签订财产份额转让协议，受让其持有的厦门云创星宸创业投资合伙企业（有限合伙）1575万元财产份 额，成为其有限合伙人之一，持有其3.00%的合伙份额。本次投资为自有资金，不构成关联交易或重大资产重组。 龙蟠科技：预计2026年宁德时代将与公司发生不超过70亿元的采购交易 龙蟠科技公告，公司与宁德时代签署了《持续关连交易协议（采购）》。协议约定，2026会计年度，宁德时代（含其附属公司及其参股30%以上公司）向公 司及公司附属公司支付的交易金额上限将不得超过公司根据《香港联合交易所有限公司证券上市规则》于香港联合交易所有限公司网站不时披露的金额。公 司预计2026年，宁德时代将与公司发生不超过70亿元的采购交易。 獐子岛：参股公司普冷獐子岛借款逾期 獐子岛公告，公司于2024年向参股公司普冷獐子岛提供1450.87万元借款，年利率6.08%，但普冷獐子岛未能按期偿还本金及罚息。该笔借款用途为生产经 营，普冷獐子岛为獐子岛关联法人。公司已发催款函，并计划进行专项审计以评估其偿债能力。此事项不会影 ...

第1笔成交价格为17.80元，成交19.64万股，成交金额349.59万元，溢价率为0.28%，买方营业部为华泰 证券股份有限公司深圳益田路证券营业部，卖方营业部为华泰证券股份有限公司深圳益田路证券营业 部。 炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 1月15日，信达证券收跌0.50%，收盘价为17.75元，发生1笔大宗交易，合计成交量19.64万股，成交金 额349.59万元。 进一步统计，近3个月内该股累计发生2笔大宗交易，合计成交金额为549.6万元。该股近5个交易日累计 下跌0.39%，主力资金合计净流入1560.46万元。 责任编辑：小浪快报 ...

证券日报网讯1月15日，信达证券（601059）在互动平台回答投资者提问时表示，截至目前，公司无应 披露未披露信息。公司将继续稳健经营、规范运作，不断提高公司核心竞争力和盈利水平，致力于为股 东创造长期价值。 ...

| 交易日期 | 证券简称 | 证券代码 | 成交价(元) 成交金额[万元] 成交量(*) 买入营业部 | 卖出营业部 是否为专场 | | --- | --- | --- | --- | --- | | 026-01-15 | 信达证券 | 601059 | 17.8 349.59 19.64 茶奇量發盤當落喔 | 不是是多意思想 ка | 1月15日，信达证券大宗交易成交19.64万股，成交额349.59万元，占当日总成交额的0.68%，成交价17.8 元，较市场收盘价17.75元溢价0.28%。 ...

信达证券股份有限公司（以下简称公司或信达证券）与中国国际金融股份有 限公司（以下简称中金公司）、东兴证券股份有限公司（以下简称东兴证券）正 在筹划由中金公司通过向东兴证券全体 A 股换股股东发行 A 股股票、向信达证 券全体 A 股换股股东发行 A 股股票的方式换股吸收合并东兴证券、信达证券（以 下简称本次交易）。本次交易预计构成《上市公司重大资产重组管理办法》规定 的重大资产重组，不构成重组上市。 信达证券股份有限公司 关于重大资产重组的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担相应的法律责任。 一、本次交易的基本情况 证券代码：601059 证券简称：信达证券 公告编号：2026-001 1 年 12 月 18 日披露的《中国国际金融股份有限公司换股吸收合并东兴证券股份有 限公司、信达证券股份有限公司预案》中详细披露了本次交易可能存在的风险因 素及尚需履行的程序，敬请广大投资者关注后续公告并注意投资风险。 特此公告。 信达证券股份有限公司董事会 二、本次交易进展情况 2026 年 1 月 15 日 2 公司于 2025 ...

中金公司公告称，公司正筹划换股吸收合并东兴证券、信达证券，预计构成重大资产重组。2025年12月 17日，公司董事会已审议通过交易预案相关议案。公司A股股票于2025年12月18日开市起复牌。截至公 告披露日，交易相关审计等工作未完成。本次交易尚需各方董事会、股东会及监管机构批准，存在不确 定性，提醒投资者关注后续公告及风险。 ...

Investment Rating - The report indicates a stable credit level for the local Asset Management Company (AMC) industry, with no rating adjustments noted for 2025 [8][39]. Core Insights - The local AMC industry is entering a phase of strict regulation, marked by the release of the "Interim Measures for the Supervision and Administration of Local Asset Management Companies" in July 2025, which establishes a unified regulatory framework [8][9]. - The industry is experiencing a trend of returning to its core business, with a reduction in the number of institutions and a clear differentiation in the competitive landscape, leading to a pronounced head effect [8][12]. - As of mid-2025, the industry has seen a slowdown in asset and net asset growth, although profitability has shown signs of recovery, and overall debt repayment risks remain moderate [8][12]. - The financing environment for local AMCs has improved, with a diversification of financing methods and a notable decrease in bond issuance costs [36][55]. Industry Policy and Regulatory Environment - The regulatory framework has shifted to a "strict regulation + encouragement of business development" approach since 2024, guiding AMCs to focus on their core business and enhance risk management [9][10]. - The new regulations require local AMCs to standardize operations and strengthen risk control, introducing quantitative regulatory indicators that will reshape the industry’s business ecology [9][10]. Industry Competition Status - The number of local AMCs has decreased, with a trend of internal license consolidation continuing, leading to a more competitive environment [12][13]. - The industry is witnessing a clear division between state-owned and private AMCs, with state-owned entities receiving more support from local governments due to their role in mitigating regional financial risks [16][18]. Industry Operating and Financial Conditions - The overall asset quality of local AMCs has been under pressure, particularly due to the real estate market downturn, which has affected asset valuations and liquidity [27][21]. - As of mid-2025, the net asset growth rate for local AMCs was recorded at 3.73%, indicating a strong capital position despite a slowdown in growth [28][29]. - Profitability indicators have shown a rebound in the first half of 2025, with total profits and net profits increasing by 25.35% and 21.13% year-on-year, respectively [30][31]. Financing and Debt Repayment Levels - The financing environment has improved, with an increase in the number of local AMCs issuing bonds, and the overall credit level remains stable [39][40]. - The industry has seen a significant decrease in bond issuance costs, with average financing costs dropping by approximately 35 basis points in 2025 [55][57]. - The debt repayment indicators are at a moderate level, with cash reserves covering short-term debts remaining stable [37][36].

Group 1 - Chengda Pharmaceutical announced that on January 14, 2026, it will accept an investor survey conducted by Cinda Securities, with participation from the company's director and general manager, Lu Gang, who will address investor inquiries [1] Group 2 - Haili Biological's acquisition of a company has seen a ninefold increase in value, yet the valuation has halved over the past eight months, raising concerns as its largest client is a company that has not yet been established [1]

Core Viewpoint - The restructuring of Xinda Australia Fund's ownership and management has led to significant changes in its operational stability and performance, raising concerns about its future growth trajectory and investor confidence [1][6]. Management Changes - In December 2025, Xinda Australia Fund underwent multiple personnel changes, including the departure of Chairman Zhu Ruimin and the appointment of Tang Lunfei as the new chairman [2][3]. - Vice General Manager Lu Li also left the company, and the former General Manager Zhu Yongqiang retired after leading the fund to grow its management scale from 10 billion to 100 billion [2][3]. - The new chairman Tang Lunfei has extensive experience in risk management and compliance, which may influence the company's future direction [2]. Fund Manager Adjustments - Several fund managers were replaced in December, with notable attention on the departure of Yang Ke, the manager of the "Xinda Health China" fund, which has seen a significant decline in performance [3][4]. - Yang Ke's management saw a drastic reduction in assets from over 7 billion to 690 million, indicating a loss of investor confidence [5]. Performance and Financial Metrics - Xinda Australia Fund reported a significant decline in revenue and net profit, with 2024 figures showing revenue of 644 million and net profit of 101 million, both down sharply year-on-year [6]. - By mid-2025, the fund's management scale dropped from 1,374.51 billion to 1,030.06 billion, with a notable decrease in money market fund size [6]. - The fund faced regulatory issues, including a penalty for insider trading, which further impacted its reputation and operational stability [6][7]. Market Position and Future Outlook - The company is at a crossroads, needing to stabilize its core team, adjust investment strategies, and rebuild investor trust amidst a changing market environment [7]. - If the company can effectively integrate internal resources and refocus on research and investment capabilities, there remains potential for regaining investor confidence as market conditions improve [7].

风险提示：提及个股仅用于行业事件分析，不构成任何个股推荐或投资建议。指数等短期涨跌仅供 参考，不代表其未来表现，亦不构成对基金业绩的承诺或保证。观点可能随市场环境变化而调整，不构 成投资建议或承诺。提及基金风险收益特征各不相同，敬请投资者仔细阅读基金法律文件，充分了解产 品要素、风险等级及收益分配原则，选择与自身风险承受能力匹配的产品，谨慎投资。 每日经济新闻 1月13日，证券ETF（512880）涨超0.3%，货币政策宽松与监管强化或提振行业预期。 信达证券指出，非银金融行业的弹性正在逐步增加，作为牛市中的底仓和稳定器具有重要配置价 值。证券板块受益于资本市场回暖及鼓励并购重组等政策影响，PB和ROE均出现小幅回升；保险板块 基本面触底后明显改善，资产端权益配置比例提升叠加市场回暖增厚利润，负债端有预定利率下调、代 理人渠道改革等支撑，ROE大幅回升但PB仅小幅修复，存在较大弹性空间。非银金融整体估值仍处长 期趋势以下偏低位置，随着政策催化及资金回流，板块有望进一步表现。 证券ETF（512880）跟踪的是证券公司指数（399975），该指数从A股市场上市的证券公司中选取 具有代表性的券商企业作为指数样本， ...